Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
暂无分享,去创建一个
H. Kitchener | M. Lehtinen | X. Castellsagué | S. Chow | D. Apter | J. Paavonen | P. Naud | J. Salmerón | U. Jaisamrarn | F. Struyf | G. Dubin | A. Szarewski | B. Romanowski | D. Descamps | W. Huh | T. Zahaf | K. Hardt | S. R. Skinner | Tino F. Schwarz | Genara Limson | Suzanne M. Garland | C. Wheeler | Julio C. Teixeira | Fred Y Aoki | Willy A J Poppe | F. Bosch | Diane M. Harper | Júlio C. Teixeira | Diane M Harper
[1] D. Lowy,et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. , 2011, Vaccine.
[2] S. Franceschi,et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication , 2011, International journal of cancer.
[3] N. Muñoz,et al. Incident Cervical HPV Infections in Young Women: Transition Probabilities for CIN and Infection Clearance , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[4] N. Muñoz,et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.
[5] T. Iftner,et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. , 2010, Journal of the National Cancer Institute.
[6] Joakim Dillner,et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. , 2010, Journal of the National Cancer Institute.
[7] S. Wacholder,et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants , 2009, International journal of cancer.
[8] B Romanowski,et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.
[9] P. Coursaget,et al. Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications , 2009, Protein science : a publication of the Protein Society.
[10] M. Schiffman,et al. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline , 2009, Infectious Agents and Cancer.
[11] K. Straif,et al. A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.
[12] C. Wheeler,et al. Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States , 2009, Journal of the National Cancer Institute.
[13] C. Wheeler,et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.
[14] R. DeSalle,et al. Evolutionary Dynamics of Variant Genomes of Human Papillomavirus Types 18, 45, and 97 , 2008, Journal of Virology.
[15] Diane Solomon,et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. , 2008, Vaccine.
[16] F. X. Bosch,et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. , 2008, Vaccine.
[17] C. Poole,et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. , 2008, American journal of epidemiology.
[18] V. Wong,et al. All that palsies is not Bell's -the need to define Bell's palsy as an adverse event following immunization. , 2007, Vaccine.
[19] M. Klein,et al. Crystal Structures of Four Types of Human Papillomavirus L1 Capsid Proteins , 2007, Journal of Biological Chemistry.
[20] Martha J. Brown,et al. Antibodies from Women Immunized with Gardasil ® Cross-Neutralize HPV 45 Pseudovirions , 2007, Human vaccines.
[21] Henry C Kitchener,et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.
[22] J. Dillner,et al. Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. , 2007, The Journal of general virology.
[23] R. Zuna,et al. Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type , 2007, Modern Pathology.
[24] H. Selinka,et al. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33 , 2006, Virology Journal.
[25] W. Quint,et al. Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR , 2006, Journal of Clinical Microbiology.
[26] M. Lehtinen,et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing , 2006, International journal of STD & AIDS.
[27] J. Berkhof,et al. Prevalence of types 16 and 33 is increased in high‐risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse , 2005, International journal of cancer.
[28] R. DeSalle,et al. The carcinogenicity of human papillomavirus types reflects viral evolution. , 2005, Virology.
[29] S. Franceschi,et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis , 2003, British Journal of Cancer.
[30] F. X. Bosch,et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.
[31] P. Coursaget,et al. Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses , 2002, Journal of Virology.
[32] N. Christensen,et al. Immunological analyses of human papillomavirus capsids. , 2001, Vaccine.
[33] C. Key,et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. , 2000, Gynecologic oncology.
[34] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[35] R. Burk,et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. , 1995, Journal of the National Cancer Institute.
[36] David R. Scott,et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. , 1994, The Journal of infectious diseases.
[37] C. Wheeler,et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. , 2012, The Lancet. Oncology.
[38] Magnus von Knebel Doeberitz,et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. , 2008, Cancer research.